• Telix Pharmaceuticals successfully prices US$600M offer of 1.50% convertible notes due 2031
• Proceeds to be used to repurchase existing A$650M convertible bonds and for general corporate purposes
• Maximum 43,308,166 new ordinary shares may be issued on conversion of the convertible notes

Telix Pharmaceuticals Limited (ASX: TLX) announced that its wholly owned subsidiary, Telix Pharmaceuticals (Investments) Inc., has successfully priced a US$600 million offer of 1.50% fully paid, guaranteed, senior, unsecured, convertible notes due 2031. The convertible notes will be convertible into fully paid ordinary shares in Telix. The net proceeds from the issue of the convertible notes will be used to facilitate the repurchase of Telix's existing A$650 million 2.375 per cent senior unsecured convertible bonds due 2029 and for general corporate purposes. The maximum number of ordinary shares that may be issued on conversion of the convertible notes at the initial Conversion Price, prior to any adjustment for customary dilutionary events, is 43,308,166 ordinary shares. The announcement provides details on the issue of the convertible notes, the effect on Telix's balance sheet, the rights and liabilities attaching to the convertible notes and ordinary shares, and Telix's compliance with disclosure obligations.